重症医学中的循证个体化医疗:量化与应用个体化治疗效应的框架
重症医学中常见综合征(如脓毒症和急性呼吸窘迫综合征)在临床和生物学上具有异质性,随机试验报告的平均治疗效应可能掩盖个体治疗反应的显著差异。本文综述了分析治疗效应异质性、预测每位患者个体化治疗效应的统计方法,并提出了推导和验证个体化治疗效应的框架。文章还识别了将个体化治疗效应估计应用于临床治疗决策所面临的挑战。
要点
- 随机试验报告的平均治疗效应可能显著不同于个体患者的实际治疗反应。
- 重症常见综合征(如脓毒症和急性呼吸窘迫综合征)的临床和生物学异质性使治疗效应异质性尤为重要。
- 已有统计方法可分析治疗效应异质性并预测每位患者的个体化治疗效应。
- 本文提出推导和验证个体化治疗效应的框架,并指出应用于临床决策的挑战。
研究设计与关键结果
- 综述指出,随机试验通常报告组间结局的聚合差异(平均治疗效应),但治疗对结局的实际效应(治疗反应)在个体间可存在显著差异,且可与平均治疗效应显著不同。
- 重症监护中常见综合征(如脓毒症和急性呼吸窘迫综合征)在临床和生物学上具有异质性,因此治疗效应异质性尤为重要。
- 已开发统计方法用于分析治疗效应异质性并预测每位患者的个体化治疗效应。
- 本综述概述了推导和验证个体化治疗效应的框架,并识别了将个体化治疗效应估计用于临床治疗决策的挑战。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Clinicians aim to provide treatments that will result in the best outcome for each patient. Ideally, treatment decisions are based on evidence from randomised clinical trials. Randomised trials conventionally report an aggregated difference in outcomes between patients in each group, known as an average treatment effect. However, the actual effect of treatment on outcomes (treatment response) can vary considerably between individuals, and can differ substantially from the average treatment effect. This variation in response to treatment between patients-heterogeneity of treatment effect-is particularly important in critical care because common critical care syndromes (eg, sepsis and acute respiratory distress syndrome) are clinically and biologically heterogeneous. Statistical approaches have been developed to analyse heterogeneity of treatment effect and predict individualised treatment effects for each patient. In this Review, we outline a framework for deriving and validating individualised treatment effects and identify challenges to applying individualised treatment effect estimates to inform treatment decisions in clinical care.
参考来源
- Munroe ES, Spicer A, Castellvi-Font A, et al. Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill. Lancet Respir Med. 2025. PMID: 40250459. doi:10.1016/S2213-2600(25)00054-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。